BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

September 15, 2026 updated by: SystImmune Inc.

A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is a Global Phase 3, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M14D1 in combination with atezolizumab compared with standard-of-care therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC). Standard-of-care therapy consists of carboplatin plus etoposide chemotherapy and atezolizumab, followed by maintenance treatment with atezolizumab with or without lurbinectedin.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
550

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Australia
    • Australian Capital Territory
      • Garran, Australian Capital Territory, Australia, 2605
        • Not yet recruiting
        • Canberra Hospital
        • Principal Investigator:
          • Geoffrey Peters
    • Queensland
      • Southport, Queensland, Australia, 4215
        • Not yet recruiting
        • Tasman Oncology
        • Principal Investigator:
          • Kenneth O'Byrne
    • South Australia
      • Bedford Park, South Australia, Australia, 5042
        • Not yet recruiting
        • Flinders Medical Centre
        • Principal Investigator:
          • Chris Karapetis
  • Bulgaria
      • Gabrovo, Bulgaria, 5300
        • Not yet recruiting
        • MHAT Dr. Tota Venkova
        • Principal Investigator:
          • Bonka Popova
      • Pleven, Bulgaria, 5800
        • Not yet recruiting
        • MHAT Heart and Brain
        • Principal Investigator:
          • Natalia Chilingirova
      • Plovdiv, Bulgaria, 1431
        • Not yet recruiting
        • Medical Centre FutureMeds
        • Principal Investigator:
          • Nikolay Shopov
      • Plovdiv, Bulgaria, 4002
        • Not yet recruiting
        • MHAT Pulmed
        • Principal Investigator:
          • Yanislav Ilieva
      • Sofia, Bulgaria, 1431
        • Not yet recruiting
        • UMHAT Sveti Ivan Rilski
        • Principal Investigator:
          • Bozhil Robrev
      • Sofia, Bulgaria, 1632
        • Not yet recruiting
        • MHAT Serdikamed
        • Principal Investigator:
          • Krasimir Koynov
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Not yet recruiting
        • Arthur Child Cancer Centre
        • Principal Investigator:
          • Vishal Navani
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
        • Not yet recruiting
        • University of Sherbrooke
        • Principal Investigator:
          • Francois Panet
  • Czechia
      • Ostrava, Czechia, 703 00
        • Not yet recruiting
        • Nemocnice Agel Vítkovice
        • Principal Investigator:
          • Jaromír Roubec
      • Ostrava-Poruba, Czechia, 708 52
        • Not yet recruiting
        • Fakultní nemocnice Ostrava (FN Ostrava)
        • Principal Investigator:
          • Radoslava Černeková
      • České Budějovice, Czechia, 370 01
        • Not yet recruiting
        • Nemocnice České Budějovice, a.s.
        • Principal Investigator:
          • Taťána Karpianusová
  • France
      • Créteil, France, 94010
        • Not yet recruiting
        • Organization Centre Hospitalier Intercommunal de Creteil (CHIC) - Centre de Recherche Clinique (CRC) (Clinical Research Center)
        • Principal Investigator:
          • Christos Chouaid
      • Lyon, France, 69008
        • Not yet recruiting
        • CLB - Centre Léon Bérard
        • Principal Investigator:
          • Romane Gille
      • Marseille, France, 13273
        • Not yet recruiting
        • IPC - lnstitut Paoli-Calmettes
        • Principal Investigator:
          • Philippe Rochigneux
      • Paris, France, 75005
        • Not yet recruiting
        • Universite Pierre et Marie Curie (UPMC) - Center de Recherche des Cordeliers (CRC)
        • Principal Investigator:
          • Nicolas Girard
      • Saint-Herblain, France, 44805
        • Not yet recruiting
        • ICO - L'Institut de Cancérologie de L'Ouest
        • Principal Investigator:
          • Ludovic Doucet
  • Georgia
      • Tbilisi, Georgia, 0114
        • Not yet recruiting
        • LTD New Hospitals
        • Principal Investigator:
          • David Giorgadze
      • Tbilisi, Georgia, 0186
        • Not yet recruiting
        • Caucasus Medical Centre
        • Principal Investigator:
          • Ivane Kiladze
      • Tbilisi, Georgia, 0114
        • Not yet recruiting
        • LTD High Technology Hospital Medcenter
        • Principal Investigator:
          • Tamta Makharadze
      • Tbilisi, Georgia, 0114
        • Not yet recruiting
        • Pineo Medical Ecosystem LtD
        • Principal Investigator:
          • Marita Gugunava
      • Tbilisi, Georgia, 0119
        • Not yet recruiting
        • LLC Todua Clinic
        • Principal Investigator:
          • Tamar Melkadze
      • Tbilisi, Georgia, 0180
        • Not yet recruiting
        • The First Medical Clinic LLC
        • Principal Investigator:
          • Nino Khupenia
  • Germany
      • Cologne, Germany, 51109
        • Not yet recruiting
        • Lungenklinik/Lungenkrebszentrum Köln-Merheim
        • Principal Investigator:
          • Birgit Saers
      • Essen, Germany, 45136
        • Not yet recruiting
        • KEM | Evangelische Kliniken Essen Mitte gGmbH
        • Principal Investigator:
          • Julia Galuba
      • Halle, Germany, 06120
        • Not yet recruiting
        • Krankenhaus Martha-Maria Halle-Dölau
        • Principal Investigator:
          • Habil. Miriam Möller
  • Greece
      • Athens, Greece, 11526
        • Not yet recruiting
        • Henry Dunant Hospital Center
        • Principal Investigator:
          • Giannis Mountzios
      • Thessaloniki, Greece, 55236
        • Not yet recruiting
        • St Luke's Hospital
        • Principal Investigator:
          • Elena Fountzila
      • Thessaloniki, Greece, 54639
        • Not yet recruiting
        • Theageneio Anticancer Hospital
        • Principal Investigator:
          • Dora Tsiouda
      • Thessaloniki, Greece, 57001
        • Not yet recruiting
        • European Interbalkan Medical Center
        • Principal Investigator:
          • Ippokratis Korantzis
  • Hungary
      • Budapest, Hungary, 1083
        • Not yet recruiting
        • Semmelweis University Department of Pulmonology
        • Principal Investigator:
          • Veronika Müller
      • Gyöngyös, Hungary, 7151
        • Not yet recruiting
        • Mátrai Gyógyintézet
        • Principal Investigator:
          • István Albert
      • Kecskemét, Hungary, 6000
        • Not yet recruiting
        • Bács-Kiskun Vármegyei Oktatókórház, Oncoradiology Center
        • Principal Investigator:
          • Judit Kocsis
      • Törökbálint, Hungary, 2045
        • Not yet recruiting
        • Református Pulmonológiai Intézet
        • Principal Investigator:
          • Gabriella Gálffy
  • Italy
      • Aviano, Italy, 33081
        • Not yet recruiting
        • Centro di Riferimento Oncologico
        • Principal Investigator:
          • Elisa Bertoli
      • Palermo, Italy, 90127
        • Not yet recruiting
        • Policlinico Paolo Giaccone University Hospital
        • Principal Investigator:
          • Valerio Gristina
      • Roma, Italy, 00168
        • Not yet recruiting
        • Fondazione Policlinico Universitario A. Gemelli IRCCS
        • Principal Investigator:
          • Emilio Bria
      • Roma, Italy, 00144
        • Not yet recruiting
        • Regina Elena Institute for Cancer Research
        • Principal Investigator:
          • Federico Cappuzzo
      • Siena, Italy, 53100
        • Not yet recruiting
        • AOUS Le Scotte, UOC Immunoterapia Oncologica
        • Principal Investigator:
          • Michele Maio
  • Poland
      • Bialystok, Poland, 15-540
        • Not yet recruiting
        • Uniwersytecki Szpital Kliniczny w Bialymstoku, II Klinika Chorob Pluc, Raka Pluca i Chorob Wewnetrznych
        • Principal Investigator:
          • Robert Mroz
      • Gdynia, Poland, 81-519
        • Not yet recruiting
        • Szpitale Pomorskie Spolka z ograniczona odpowiedzialnoscia, Oddzial Onkologii i Radioterapii - Dzial Onkologii Klinicznej
        • Principal Investigator:
          • Magdalena Wroblewska
      • Katowice, Poland, 40-514
        • Not yet recruiting
        • Oddzial Onkologii Klinicznej
        • Principal Investigator:
          • Jacek Kabut
      • Lodz, Poland, 93-338
        • Not yet recruiting
        • Instytut "Centrum Zdrowia Matki Polki", Klinika Onkologii
        • Principal Investigator:
          • Ewa Kalinka
      • Prabuty, Poland, 82-550
        • Not yet recruiting
        • Szpital Specjalistyczny w Prabutach Spolka z ograniczona odpowiedzialnoscia, Oddzial pulmonologii
        • Principal Investigator:
          • Anna Lowczak
  • Serbia
      • Belgrade, Serbia, 11000
        • Not yet recruiting
        • University Clinical Centre of Serbia, Clinic for pulmonology
        • Principal Investigator:
          • Natalija Samardzic
      • Belgrade, Serbia, 11000
        • Not yet recruiting
        • University Hospital Medical Center Bezanijska Kosa
        • Principal Investigator:
          • Zoran Andric
      • Kragujevac, Serbia, 34000
        • Not yet recruiting
        • University Clinical Center Kragujevac
        • Principal Investigator:
          • Jasmina Nedovic
      • Novi Sad, Serbia, 21208
        • Not yet recruiting
        • Institute for pulmonary diseases of Vojvodina
        • Principal Investigator:
          • Goran Stojanovic
  • Spain
      • A Coruña, Spain, 15006
        • Not yet recruiting
        • Complejo Hospitalario Universitario A Coruna (CHUAC) - Hospital Teresa Herrera
        • Principal Investigator:
          • Maria Rosario Garcia-Campelo
      • Barcelona, Spain, 08041
        • Not yet recruiting
        • Hospital de La Santa Creu i Sant Pau
        • Principal Investigator:
          • Margarita Majem Tarruella
      • Las Palmas de Gran Canaria, Spain, 35016
        • Not yet recruiting
        • Hospital Universitario Insular de Gran Canaria
        • Principal Investigator:
          • Delvys Rodríguez-Abreu
      • Madrid, Spain, 28040
        • Not yet recruiting
        • Hospital Clinico San Carlos
        • Principal Investigator:
          • Carlos Aguado de la Rosa
      • Madrid, Spain, 28050
        • Not yet recruiting
        • Centro de Investigación Oncológica Clara Campal
        • Principal Investigator:
          • Gema Garcia Ledo
  • United States
    • Arkansas
      • Springdale, Arkansas, United States, 72762
        • Not yet recruiting
        • Highlands Oncology Group
        • Principal Investigator:
          • Eric Schaefer
    • California
      • Glendale, California, United States, 91203
        • Recruiting
        • Los Alamitos Hematology/Oncology Medical Group
        • Principal Investigator:
          • Michael Nguyen
      • Long Beach, California, United States, 90806
        • Recruiting
        • MemorialCare Todd Cancer Institute
        • Principal Investigator:
          • Nilesh Vora
      • Los Angeles, California, United States, 90067
        • Recruiting
        • Valkyrie Clinical Trials
        • Principal Investigator:
          • David Berz
        • Contact:
    • Florida
      • Miami, Florida, United States, 33176
        • Not yet recruiting
        • Total Health and Research Center
        • Principal Investigator:
          • Francisco Belette
    • New Jersey
      • East Brunswick, New Jersey, United States, 08816
        • Recruiting
        • Astera Cancer Care
        • Principal Investigator:
          • Neel Belani
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • Virginia Cancer Specialists
        • Principal Investigator:
          • Alexander Spira

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)
  • Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.
  • At least one measurable lesion based on RECIST v1.1 per investigator assessment.
  • An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
  • Adequate organ function

Exclusion Criteria:

  • Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.
  • Participants who have received prior topoisomerase inhibitor-based ADC therapy.
  • Participants with history of severe heart disease
  • Participants with active autoimmune diseases and inflammatory diseases,
  • Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years
  • Other protocol-defined inclusion/exclusion criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Arm A
BL-M14D1: Administered on days 1 of every 21 days Atezolizumab: Administered dose on days 1 of every 21 days
Drug: BL-M14D1 and Atezolizumab
BL-M14D1 administered in combination with atezolizumab. BL-M14D1 will be given intravenously at the protocol-specified dose and schedule. Atezolizumab will be administered intravenously according to the approved dosing regimen.
Other Names:
  • Atezolizumab
  • BL-M14D1
Experimental: Arm B
BL-M14D1: Administered on days 1 of every 21 days Atezolizumab: Administered dose on days 1 of every 21 days
Drug: BL-M14D1 and Atezolizumab
BL-M14D1 administered in combination with atezolizumab. BL-M14D1 will be given intravenously at the protocol-specified dose and schedule. Atezolizumab will be administered intravenously according to the approved dosing regimen.
Other Names:
  • Atezolizumab
  • BL-M14D1
Active Comparator: Arm C

Medications used in the Control Arm should be administered per local label or institutional guidelines.

Induction therapy (4 cycles):

Carboplatin (AUC of 5 mg/mL*min IV) on Day 1 of each 21-day cycle Etoposide (100 mg/m2 IV) on Days 1 through 3 of each 21-day cycle Atezolizumab (1200 mg) IV on Day 1 of each 21-day cycle

Maintenance therapy (continues until discontinuation criteria are met):

Atezolizumab (1200 mg) IV on Day 1 of each 21-day cycle Lurbinectedin (3.2 mg/m2) IV on Day 1 of each 21-day cycle (to be added only if approved in region and as per PI discretion)
Drug: Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
Carboplatin and etoposide will be administered intravenously in combination with atezolizumab for induction therapy, followed by maintenance treatment with atezolizumab with or without lurbinectedin per protocol.
Other Names:
  • Carboplatin
  • Etoposide
  • Atezolizumab
  • Lurbinectedin

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)
Time Frame: Up to approximately 2 years
Progression-free survival (PFS) is defined as the time from randomization to the first documented disease progression, as assessed by blinded independent central review (BICR) according to RECIST v1.1, or death from any cause, whichever occurs first.
Up to approximately 2 years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Overall Survival (OS)
Time Frame: Up to approximately 2 years
Overall survival (OS) is defined as the time from randomization to death from any cause.
Up to approximately 2 years
Participants with Serious Adverse Events (SAEs)
Time Frame: Up to approximately 5 years
Measuring the number of participants with serious adverse events (SAEs)
Up to approximately 5 years
Participants with treatment-emergent adverse events (TEAEs)
Time Frame: Up to approximately 5 years
Measuring the number of participants with Treatment-emergent adverse events (TEAEs) leading to discontinuation
Up to approximately 5 years
Evaluate the safety of BL-M14D1 in combination with atezolizumab
Time Frame: Up to approximately 5 years
Death
Up to approximately 5 years
Participants with abnormal lab results
Time Frame: Up to approximately 5 years
Measure number of participants with abnormal laboratory results
Up to approximately 5 years
To compare and quantify the impact of BL-M14D1 in combination with atezolizumab on participants' quality of life and functional status
Time Frame: Up to 5 years
Participant Reported Outcome (PRO) using 2 European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)
Up to 5 years
Overall Response Rate (ORR)
Time Frame: Up to 5 years
To assess the clinical efficacy of BL-M14D1 as measured by ORR using RECIST criteria v 1.1 per BICR and investigator
Up to 5 years
Disease Control Rate (DCR)
Time Frame: Up to 5 years
To assess the clinical efficacy of BL-M14D1 as measured by DCR using RECIST criteria v 1.1 per BICR and investigator
Up to 5 years
Duration Of Response (DOR)
Time Frame: Up to 5 years
To assess the clinical efficacy of BL-M14D1 as measured by DOR using RECIST criteria v 1.1 per BICR and investigator or death from any cause, whichever occur first
Up to 5 years
Time To Response (TTR)
Time Frame: Up to 5 years
To assess the clinical efficacy of BL-M14D1 as measured by TTR using RECIST criteria v 1.1 per BICR and investigator
Up to 5 years
Progression Free Survival (PFS)
Time Frame: Up to 5 years
To assess the clinical efficacy of BL-M14D1 as measured by PFS using RECIST criteria v 1.1 by investigator or death from any cause, whichever occurs first
Up to 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
SystImmune Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Junliang Cai, MD, SystImmune Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 4, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 1, 2030

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2031

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
May 21, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 28, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 4, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 15, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BL-M14D1-LC-301

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings